Abstract
Invasive fungal infections have emerged as one of the most significant complications in severely immunocompromised pediatric patients, such as children suffering from hematological malignancies or children undergoing hematopoietic stem cell transplantation. In addition, neonates, in particular preterm infants, are at risk for invasive mycoses. Owing to the development of new generations and new classes of antifungal compounds, the antimycotic armamentarium has considerably expanded over the last few years. Caspofungin is the first licensed compound of the novel class of echinocandin lipopeptides. This article reviews the published data on the experience with caspofungin in neonates and immunocompromised children.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.